In the present study, AMPK expression was the dual target for FD/LCS and drug treatment in that Met/Rap treatment of the FD/LCS mice sustained the FD/LCS-activated AMPK expression with deactivation of mTOR/HIF-1α signaling and its downstream protein expressions. This evidence concerns the gene HIF1A and Fabry disease.